Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M

Olema Pharmaceuticals, Inc.

Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.
Selected 90 mg once-daily palazestrant for OPERA-01 Part 2 and OPERA-02 frontline combo trial with ribociclib.
OPERA-01 top-line data expected H2 2026; OPERA-02 initiation on track for Q3 2025.
Cash, equivalents, and marketable securities $361.9M as of June 30, 2025.
Mature palazestrant+ribociclib Phase 1b/2 data to be presented at ESMO 2025; OP-3136 Phase 1 enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.